A phase I study of cisplatin, etoposide, and paclitaxel in small cell lung cancer: A University of Colorado Cancer Center Study

P. A. Bunn, Karen Kelly, Young, Greco, D. Johnson

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

The University of Colorado Cancer Center is conducting a phase I study of the three-drug PET combination of cisplatin, etoposide, and paclitaxel (Taxol; Bristol-Myers Squibb Company, Princeton, NJ) in patients with advanced (stage IV or IIIB with pleural effusion) small cell lung cancer. The primary study goal was to define the maximally tolerated doses given on an outpatient basis. Secondary goals were to determine toxicities, response rate, response duration, and survival. Paclitaxel was given as a 3-hour intravenous (IV) infusion prior to cisplatin and etoposide. The starting doses were paclitaxel 135 mg/m2 day 1, cisplatin 80 mg/m2 IV day 1, and etoposide 50 mg/m2 IV day 1, and 100 mg/m2 orally days 2 and 3, every 3 weeks. In the second group, the etoposide was increased to 80 mg/m2 IV day 1 and 160 mg/m2 orally days 2 and 3. In the third group, paclitaxel was increased to 175 mg/m2 IV day 1. Granulocyte colony-stimulating factor was not given on the first cycle, but was given on subsequent cycles if grade 4 neutropenia developed. So far, 13 patients have been entered on the study; all are evaluable for toxicity and nine are evaluable for response. The major toxicity was neutropenia, with no other grade 4 toxicities observed. All patients received the full six cycles of therapy. Thus far, partial responses have been observed in four patients (44%) and complete responses in five patients (56%), for an overall response rate of 100%. This ongoing study has shown that full doses of each of these three active drugs can be administered safely on an outpatient basis. The encouraging early results should lead to a multicenter phase II evaluation of the PET combination.

Original languageEnglish (US)
Pages (from-to)54-60
Number of pages7
JournalSeminars in Oncology
Volume22
Issue number5 SUPPL. 12
StatePublished - 1995
Externally publishedYes

Fingerprint

Small Cell Lung Carcinoma
Etoposide
Paclitaxel
Neoplasms
Neutropenia
Cisplatin
Outpatients
Maximum Tolerated Dose
Granulocyte Colony-Stimulating Factor
Drug Combinations
Pleural Effusion
Intravenous Infusions
TP protocol
Survival
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Oncology

Cite this

A phase I study of cisplatin, etoposide, and paclitaxel in small cell lung cancer : A University of Colorado Cancer Center Study. / Bunn, P. A.; Kelly, Karen; Young; Greco; Johnson, D.

In: Seminars in Oncology, Vol. 22, No. 5 SUPPL. 12, 1995, p. 54-60.

Research output: Contribution to journalArticle

@article{9dcd27274b2c4bb9a7a72afa32125c82,
title = "A phase I study of cisplatin, etoposide, and paclitaxel in small cell lung cancer: A University of Colorado Cancer Center Study",
abstract = "The University of Colorado Cancer Center is conducting a phase I study of the three-drug PET combination of cisplatin, etoposide, and paclitaxel (Taxol; Bristol-Myers Squibb Company, Princeton, NJ) in patients with advanced (stage IV or IIIB with pleural effusion) small cell lung cancer. The primary study goal was to define the maximally tolerated doses given on an outpatient basis. Secondary goals were to determine toxicities, response rate, response duration, and survival. Paclitaxel was given as a 3-hour intravenous (IV) infusion prior to cisplatin and etoposide. The starting doses were paclitaxel 135 mg/m2 day 1, cisplatin 80 mg/m2 IV day 1, and etoposide 50 mg/m2 IV day 1, and 100 mg/m2 orally days 2 and 3, every 3 weeks. In the second group, the etoposide was increased to 80 mg/m2 IV day 1 and 160 mg/m2 orally days 2 and 3. In the third group, paclitaxel was increased to 175 mg/m2 IV day 1. Granulocyte colony-stimulating factor was not given on the first cycle, but was given on subsequent cycles if grade 4 neutropenia developed. So far, 13 patients have been entered on the study; all are evaluable for toxicity and nine are evaluable for response. The major toxicity was neutropenia, with no other grade 4 toxicities observed. All patients received the full six cycles of therapy. Thus far, partial responses have been observed in four patients (44{\%}) and complete responses in five patients (56{\%}), for an overall response rate of 100{\%}. This ongoing study has shown that full doses of each of these three active drugs can be administered safely on an outpatient basis. The encouraging early results should lead to a multicenter phase II evaluation of the PET combination.",
author = "Bunn, {P. A.} and Karen Kelly and Young and Greco and D. Johnson",
year = "1995",
language = "English (US)",
volume = "22",
pages = "54--60",
journal = "Seminars in Oncology",
issn = "0093-7754",
publisher = "W.B. Saunders Ltd",
number = "5 SUPPL. 12",

}

TY - JOUR

T1 - A phase I study of cisplatin, etoposide, and paclitaxel in small cell lung cancer

T2 - A University of Colorado Cancer Center Study

AU - Bunn, P. A.

AU - Kelly, Karen

AU - Young,

AU - Greco,

AU - Johnson, D.

PY - 1995

Y1 - 1995

N2 - The University of Colorado Cancer Center is conducting a phase I study of the three-drug PET combination of cisplatin, etoposide, and paclitaxel (Taxol; Bristol-Myers Squibb Company, Princeton, NJ) in patients with advanced (stage IV or IIIB with pleural effusion) small cell lung cancer. The primary study goal was to define the maximally tolerated doses given on an outpatient basis. Secondary goals were to determine toxicities, response rate, response duration, and survival. Paclitaxel was given as a 3-hour intravenous (IV) infusion prior to cisplatin and etoposide. The starting doses were paclitaxel 135 mg/m2 day 1, cisplatin 80 mg/m2 IV day 1, and etoposide 50 mg/m2 IV day 1, and 100 mg/m2 orally days 2 and 3, every 3 weeks. In the second group, the etoposide was increased to 80 mg/m2 IV day 1 and 160 mg/m2 orally days 2 and 3. In the third group, paclitaxel was increased to 175 mg/m2 IV day 1. Granulocyte colony-stimulating factor was not given on the first cycle, but was given on subsequent cycles if grade 4 neutropenia developed. So far, 13 patients have been entered on the study; all are evaluable for toxicity and nine are evaluable for response. The major toxicity was neutropenia, with no other grade 4 toxicities observed. All patients received the full six cycles of therapy. Thus far, partial responses have been observed in four patients (44%) and complete responses in five patients (56%), for an overall response rate of 100%. This ongoing study has shown that full doses of each of these three active drugs can be administered safely on an outpatient basis. The encouraging early results should lead to a multicenter phase II evaluation of the PET combination.

AB - The University of Colorado Cancer Center is conducting a phase I study of the three-drug PET combination of cisplatin, etoposide, and paclitaxel (Taxol; Bristol-Myers Squibb Company, Princeton, NJ) in patients with advanced (stage IV or IIIB with pleural effusion) small cell lung cancer. The primary study goal was to define the maximally tolerated doses given on an outpatient basis. Secondary goals were to determine toxicities, response rate, response duration, and survival. Paclitaxel was given as a 3-hour intravenous (IV) infusion prior to cisplatin and etoposide. The starting doses were paclitaxel 135 mg/m2 day 1, cisplatin 80 mg/m2 IV day 1, and etoposide 50 mg/m2 IV day 1, and 100 mg/m2 orally days 2 and 3, every 3 weeks. In the second group, the etoposide was increased to 80 mg/m2 IV day 1 and 160 mg/m2 orally days 2 and 3. In the third group, paclitaxel was increased to 175 mg/m2 IV day 1. Granulocyte colony-stimulating factor was not given on the first cycle, but was given on subsequent cycles if grade 4 neutropenia developed. So far, 13 patients have been entered on the study; all are evaluable for toxicity and nine are evaluable for response. The major toxicity was neutropenia, with no other grade 4 toxicities observed. All patients received the full six cycles of therapy. Thus far, partial responses have been observed in four patients (44%) and complete responses in five patients (56%), for an overall response rate of 100%. This ongoing study has shown that full doses of each of these three active drugs can be administered safely on an outpatient basis. The encouraging early results should lead to a multicenter phase II evaluation of the PET combination.

UR - http://www.scopus.com/inward/record.url?scp=0028866640&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028866640&partnerID=8YFLogxK

M3 - Article

C2 - 7481862

AN - SCOPUS:0028866640

VL - 22

SP - 54

EP - 60

JO - Seminars in Oncology

JF - Seminars in Oncology

SN - 0093-7754

IS - 5 SUPPL. 12

ER -